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Impact of Prospective Screening for Multiple Endocrine Neoplasia
Type 2
Robert F. Gagel,* Armen H. Tashjian, Jr, Tim Cummings, Nick Papathanasopoulos,
and Seymour Reichiin

Prospective annual screening for hereditary medullary thyroid carcinoma (MTC) in the J-kindred,
currently a 117-memberfamily with multiple endocrine neoplasia type 2A, began in 1969. During the
initial screening, 12 patients were found to have MTC. Subsequent screening has detecied C-cell
abnormalities (C-cell hyperplasia or microscopic MTC) in 22 of 23 addilional family members
thyroidectomized for abnormal calcium- or pentagastrin-provocative calcitonin (CT) test results.
Seven of the initial 12 patients thyroidectomized in 1970 to 1971 and 19 of 23 individuals
thyroidectomized since 1971 remain disease-free by all criteria; three patients thyroidectomized since
1971 have had clearly abnormal serum CT measurements on one or more provocative tests. The
significance of these abnormal tesl results is unclear because normal values were obtained when the
samples were measured in another CT radioimmunoassay. Urine catecholamine abnormalities have
been detected in 19 family members since 1969, resulting in ten bilateral and eight unilateral
adrenalectomies. Four of the patients with initial unilateral adrenalectomy required reoperation for a
pheochromocytoma in the contralateral gland nine to 13 years later. Hyperparathyroidism has not
been observed in any ofthe family members with early C-cell disease. We conclude that prospective
screening for hereditary MTC predicts histologic C-cell abnormalities in affected individuals, and
follow-up ofthese patients provides supportfor the conclusion that early thyroidectomy is curative in
most patients. (Henry Ford Hosp Med J 1987:35:94-8)

P

rospective screening for hereditary medullary thyroid
carcinoma (MTC) began in 1969 when Melvin et al (1,2)
studied J-kindred members, descendants from a large Swedish
family affected with this disease (3), to determine whether
measurement of semm calcitonin (CT) could correctly predict
the presence of MTC. In their inifial screening of the family, 12
individuals were found to have abnormal semm CT levels after a
provocative calcium (Ca) infusion. Thyroidectomy in each
of these individuals showed bilateral foci of MTC (1). Since the
initial screening of the family, each unaffected family member
over the age of five has been screened with a provocative Ca or
pentagastrin test on a regular basis (annually in most cases) to
determine whether it is possible to detect hereditary MTC in its
earliest stages and effect a cure by total thyroidectomy. Previous
reports from this study have shown that prospective screening
detects early abnormalities of C-cells prior to the development
of metastasis (4,5). Members of this kindred also have been
shown to develop parathyroid abnormalities and adrenal medullary disease including pheochromocytoma (2,4) and adrenal
medullary hyperplasia (4,6), This report focuses on the clinical
course of those individuals prospectively screened for the abnormalities associated with this syndrome and describes the management used in this family.
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Patients and Methods
Screening for MTC
The J-kindred is a large family (currently 117 members) with
multiple endocrine neoplasia type 2A (MEN-2A) (2). Procedures used for the study of CT secretion in this family have
been described (1,2,4,5). Each pafient over the age of five has
undergone a yearly Ca (15 mg elemental Ca/kg body weight) or
pentagastrin (0.5 |xg/kg, administered as an intravenous bolus
over five seconds) test. Serum CT was measured by radioimmunoassay (RIA) (7) at appropriate time points as described
(1,4,5). Basal serum CT concentrations in normal subjects
ranged from nondetectable to 380 pg/mL; Ca or pentagastrinstimulated levels did not exceed 550 pg/mL. Thyroidectomy
has been recommended if the patient has shown an abnormal CT
secretory response to at least two separate provocative tests.
Total thyroidectomy was performed by the method of Crile (8).
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Histologic techniques for analysis of thyroid tissue and the
criteria used for diagnosis of C-cell hyperplasia or carcinoma
have been described (9).
During the past two years a more sensitive CT RIA has been
used in addition to the standard assay. The kit for this assay
(40-2125) was obtained from Nichols Institute Diagnosfics (San
Juan Capistrano, CA). This assay has a reported sensitivity of 3
pg/mL, and normal basal values are 3 to 36 pg/mL for men and 2
to 17 pg/mL for women. After a pentagastrin injection, normal
stimulated values ranged from 6 to 106 pg/mL in men and 3 to 29
pg/mL in women. Adrenal medullary function was assessed by
measurement of urine epinephrine and norepinephrine as described (4). Parathyroid hormone and semm Ca were measured
by the Nichols Institute Reference Laboratories (San Juan Capistrano, CA), using a C-terminal RIA (1974 to 1983) and a midregion assay (1984 to 1986).

Results
Clinical course of patients with MTC and C-cell hyperplasia
Thirty-five family members have been thyroidectomized
since the start of prospective screening in 1969 (Fig 1). The operative and pathologicfindingsin the initial 12 patients (mean age
38.5 years) thyroidectomized between 1969 and 1971 have been
reported (1,2). All of these patients had bilateral foci of MTC,
seven of 12 with documented local nodal metastasis. An additional 23 patients (mean age 11.8 years) have been thyroidectomized since 1971 for the development of abnormal CT levels
after provocative testing. Histologic examination of the thyroid
gland showed C-cell hyperplasia in 13 patients, combined microscopic MTC and C-cell hyperplasia in nine patients, and no
histologic abnormality in one patient (considered to be a falsepositive test result) (4,5). None of the patients had histologic
evidence of metastatic disease in local lymph nodes.
The 12 patients thyroidectomized during the initial screening
have been followed annually or biannually in most cases (mean
follow-up period of 14.5 years) with provocative tests (Ca or
pentagastrin). Three of the 12 patients have died. One died secondary to metastatic rectal carcinoma (family tree #3, Fig 1),
and another died from metastatic breast carcinoma (family tree
#32, Fig 1), although both these patients were thought to have
metastatic MTC because of persistent elevations of the semm CT
after thyroidectomy. A third patient (family tree #1, Fig 1), as
previously reported (6), died of coronary artery disease at age
64 with nondetectable CT levels after provocative testing and
no disease detected at autopsy. Of the remaining nine living
patients, seven have had consistently normal test results since
thyroidectomy, whereas two are considered to have metastatic disease because of elevated CT levels basally or after
provocative testing.
The 22 family members thyroidectomized for early C-cell
disease between 1972 and 1983 have been followed with annual
or biannual testing for a mean of 11 years. Thyroidectomy led
to a reduction in the peak serum CT after a provocative pentagastrin test in each case. Nineteen of the 22 pafients have had
normal test results. Three of the 22 patients have had clearly abnormal CT levels either basally or after a pentagastrin test on
one or more occasions, although there was no other clinical evidence of metastatic disease. Aliquots of the semm samples from
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Fig 1—Pedigree of the J-kindred. The numbers 1 through 8
shown for the second generation can be used to identify specific
family members. For example, the propositus (marked with an
arrow) is the second son ofpatient #4 (family tree #42) and his
two sons would have family tree #421 and #422. A crossbar
through the individual symbol indicates the patient is dead. The
individual labeled O is the individual born in the 1880s listed as
J in the pedigree ofthe large Swedish kindred shown in Fig 1 of
the paper by Telenius-Berg et al (3). This family tree was prepared according to March of Dimes criteria (Grendel Co, PO
Box 733, Charleston, SC 29402).

the three patients with abnormal test results and two others with
borderline test results from the most recent round of testing were
assayed in our standard CT RIA and the Nichols RIA (Table). A
comparison of values shows that all of the sera considered to be
abnormal in our assay gave normal values when tested in the
Nichols assay.

Parathyroid hormone measurements
Parathyroid hyperplasia is a prominent manifestation of the
MEN-2A syndrome (2,10-13), and previous studies in this
family have demonstrated elevated parathyroid hormone (PTH)
values in 40% of family members. In addition, parathyroid
hyperplasia was found in ten of the 12 original members
thyroidectomized between 1969 and 1971, and four of 12 had a
history of renal stones (2). To determine whether clinically apparent parathyroid disease preceded C-cell abnormalities,
semm Ca levels were measured in all patients thyroidectomized
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Table
Comparison of Abnormal or Borderline Basal or
Stimulated Calcitonin Values in Two Radioimmunoassays
Family Tree
Number

Type of
Sample

412
313
413
422
431

S
S
B
B
S

Assay 1
Assay 2
(calcitonin pg/mL)
1,000
890
450
630
650

6
8
7
5
6

Basal (B) or peak stimulated (S) serum calcitonin during a pentagastrin test.
Assay 1 is our standard calcitonin radioimmunoassay, and assay 2 is the Nichols
radioimmunoassay.

for early C-cell abnormalities. The semm Ca concentration was
within the normal range in all patients. The serum PTH concentration was normal in seven of nine patients in whom measurements were made and was minimally elevated ( < 5% above
the upper limit of normal) in two patients. Postoperative PTH
concentrations were available on 15 patients a mean of 9.9 years
after thyroidectomy and were within the normal range for all patients. The semm Ca concentration has remained normal in all
thyroidectomized patients with one exception. A 20-year-old
woman (family tree #133, Fig 1) previously thyroidectomized
(C-cell hyperplasia) with prethyroidectomy and postthyroidectomy normocalcemia developed hypercalcemia (serum
Ca 10.5 to 11.6 mg%) with mid-normal PTH concentrations.
She also had symptoms of a pheochromocytoma and urine
catecholamine abnormalities. Following bilateral pheochromocytoma removal, her semm Ca normalized, and semm
Ca and PTH measurements have remained normal (highest Ca
value 10.3 mg) for nine years. We think it likely that the hypercalcemia was caused by the pheochromocytoma because of the
immediate drop in the semm Ca after bilateral adrenalectomy.
Adrenal medullary disease
Nineteen patients have developed urine catecholamine abnormalities, which have resulted in ten bilateral adrenalectomies
and eight unilateral adrenalectomies. The histologic lesion
found at surgery in these patients was pheochromocytoma on a
background of diffuse adrenal medullary hyperplasia in all adrenal glands except one in which adrenal medullary hyperplasia
was noted. One patient (patient #7, Fig 1, who was thyroidectomized before 1969) with abnormal urine catecholamine levels
declined adrenal surgery because of widely metastatic
MTC, Postmortem examination showed bilateral pheochromocytomas. Another patient with proven MTC diagnosed
before 1969 (patient #13, Fig 1) had been followed for 15 years
with normal urine catecholamine levels. During the most recent
testing, this 51-year-old woman was noted to have a 24-hour
urine epinephrine two times the upper limit of normal. Because
she was taking sympathomimetic dmgs and theophylline for allergic lung disease, repeat urine catecholamine determinations
with the patient off the medications were requested. She died
suddenly before the repeat study could be done; a postmortem
examination was not performed. Although the exact circumstances surrounding her death are unclear, the single urine
catecholamine abnormality and her sudden death suggest the
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possibility of adrenal medullary disease. A third patient (family
tree # 1 , Fig I) with proven MTC, not included in these 19
patients because of consistently normal urine catecholamine
levels, died of well-documented coronary artery disease at
age 64 and at autopsy was shown to have bilateral adrenal
medullary hyperplasia (6).
Four of the eight patients who underwent unilateral adrenalectomy have required removal of the contralateral adrenal gland
nine to 13 years after initial adrenalectomy because of the development of urine catecholamine abnormalities and symptoms
consistent with pheochromocytomas. Fig 2 shows longitudinal
urine catecholamine measurements in one of these patients,
which indicates that they may go for a prolonged period before
requiring contralateral adrenalectomy. The other four patients
with unilateral adrenalectomy have been followed for one, 11,
15, and 17 years without developing symptoms of pheochromocytomas or catecholamine abnormalities.

Discussion
Prospective screening for hereditary MTC
The value of prospective screening in the early detection of Ccell abnormalities has been established in this family (4,5) and
several other kindreds (14-19). In each of our family members
who developed disease, we were able to detect C-cell abnormalities before the development of local metastatic disease. In
this family it appears that initiation of screening by the age of
five years is adequate for detection of disease (20), but this may
not be the case in all kindreds. In another large kindred with
MEN-2A, one patient had an abnormal provocative CT test result on initial screening at age six with micrometastasis to local
lymph nodes found at surgery (personal communication,
Cynthia Torony). We have continued to recommend that screening start at age five in the J-kindred, but recognize that it
might be necessary to initiate screening at an earlier age in
other kindreds.
The most important finding in this study is absence of detectable disease in 19 of 22 patients a mean of ten years after thyroidectomy for C-cell disease. In the patients with abnormal or
borderline values in our RIA, we performed CT measurements
using a more sensitive assay and found normal CT values. Studies are currently underway to assay these same samples in the
two-site immunoradiometric assay described by Motte et al (21).
Although the abnormal values in our standard RIA may be
artifactual, a problem seen in all CT RIAs (7,22,23), it will be
important to determine whether there is persistent or recurrent
MTC because of the possible application of recently described
microsurgical approaches to this group of patients (24). Although we are optimistic at this time that thyroidectomy has resulted in a cure for this group of patients, continued follow-up
for an additional ten to 20 years will be required before such a
conclusion can be firmly stated.
Lack of evidence for parathyroid disease in early
hereditary MTC
Our studies show that semm Ca and PTH values are normal
prior to and ten years after thyroidectomy. This is in contrast
to earlier studies in this and other families with advanced.
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untreated MTC in which clinically detectable parathyroid
abnormalities have been found in 10% to 20% of affected family
members (2,10-13). Our findings make it difficult to support
the hypothesis that the C-cell abnormalities in this disease
are the result of chronic hypercalcemia caused by hyperparathyroidism, a concept proposed earlier (2,10). The one case
of hypercalcemia noted in the patients with early C-cell disease
occurred in association with bilateral pheochromocytomas.
Adrenal medullary disease
Management of adrenal medullary disease in this syndrome is
difficult, and the correct therapeutic approach is controversial.
We have removed only those adrenal glands which had a pheochromocytoma or distinct adrenal medullary enlargement
demonstrable by angiography (before 1977), computed tomography, or magnetic resonance imaging scanning. Each patient
with documented unilateral disease was offered bilateral adrenalectomy at thetimeof the primary operation, but all declined.
The contralateral adrenal gland is routinely examined at surgery
and removed if the operative findings do not confirm the radiologic evaluation. Of eight patients treated with unilateral
adrenalectomy, it has been necessary to remove the contralateral
adrenal gland in four patients an average of ten years after the
primary operation; these results are not dissimilar to those
described by other investigators (25). Other investigators have
recommended bilateral adrenalectomy at the primary operation
because of a family history of adrenal medullary malignancy
(26-28) or because of concem about therisksof a second operation to remove the contralateral adrenal gland. We have not
observed adrenal medullary malignancy in the J-kindred, and
recognize that risks are associated with development of adrenal
insufficiency following bilateral adrenal removal and that a different set ofrisksare associated with the removal of only a single
adrenal gland. We have tried to minimize the total risk by combining unilateral adrenalectomy, where appropriate, with yeariy
postoperative urine catecholamine measurements. Continued
follow-up is necessary before firm conclusions can be drawn
about the correct management of adrenal medullary disease in
this syndrome.
Prospective screening for the several manifestations of
MEN-2 has had a positive impact on the quality of life for this
family and may prove, with continued follow-up, to have provided a cure for the malignant manifestations ofthe syndrome.
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Fig 2 — Twenty-four hour urine epinephrine and the epinephrine/norepinephrine ratio in a patient (family tree #22)
who had a left adrenalectomy in 1974. After adrenalectomy, the
24-hour urine epinephrine excretion arul the epinephrine!norepinephrine ratio returned to normal for nine years before
development of symptoms and objective demonstration of a
pheochromocytoma led to the removal ofthe contralateral adrenal gland. Each point in the upper panel shows the results ofa
single 24-hour urine collection. The points in the lower panel
show the epinephrine/norepinephrine ratio calculated by dividing the 24-hour excretion of epinephrine by the 24-hour excretion of norepinephrine as previously described (4,29). The
dotted line in each panel shows the upper limit of normal for
each measurement.
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"Disease is very old and nothing about it has changed. It is we who change
as we learn to recognize what was formerly imperceptible."
J.M. Charcot (1825-1893)
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